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Correlations of ADAS-Cog and MMSE with category
scores were highest with paranoid/delusions (r = 0.25,
ADAS-Cog; r = -0.16, MMSE) and activity disturbances
(r = 0.25, ADAS-Cog; r = -0.25, MMSE). The weakest
relationships, not statistically signiﬁcant, were found on
aggressiveness (r = 0.01, ADAS-Cog; r = -0.06, MMSE)
and diurnal rhythm (r = -0.12, ADAS-Cog; r = 0.09,
MMSE). CONCLUSIONS: Given the relatively low cor-
relations (r < 0.40) of the BEHAVE-AD-FW with ADAS-
Cog and MMSE, the BEHAVE-AD-FW may measure
previously undetected symptoms of dementia in AD and
might be an independent supplement to measures of 
cognition.
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OBJECTIVES: To assess an inﬂuence of depression,
dementia, disease severity and motor complications on
the Quality of Life (QoL) in Parkinson’s Disease (PD).
METHODS: Quality of Life was measured in 241
patients with PD (male: 127, female: 114, mean age: 66.1
± 7.5, duration of disease: 5.2 ± 3.2) using the Parkinson
Disease Questionnaire (PDQ-39), a disease-speciﬁc
instrument. Dementia was evaluated by using the MMSE
and depression was evaluated by Hamilton Rating Scale
(HAM). Disease severity and motor function were
recorded with the Hoehn and Yahr scale and the UPDRS
II-IV. Spearman’s correlation coefﬁcient was used to 
calculate correlation scores. RESULTS: All domains of
PDQ-39 signiﬁcantlty correlated with depressive symp-
toms. Signiﬁcant correlation between HAM scores and
PDQ-39 summary index (R = 0.53, p < 0.001) was
observed. PDQ-39 also correlated with UPDRS II (R =
0.67, p < 0.001), UPDRS III (R = 0.49, p < 0.001) and
HY stage (R = 0.62, p < 0.001). Motor ﬂuctuations and
dyskinesias (UPDRS IV) had signiﬁcant impact on QoL
(R = 0.57, p < 0.001). Dementia or cognitive impairment
had a minor correlation with UPDRS III and HY stage (R
= -0.32, p < 0.001 and R = -0.44, p < 0.001, respectively)
but had no correlation with PDQ-39. CONCLUSIONS:
Disease severity, motor ﬂuctuations, and depression inﬂu-
ence on QoL in patients with Parkinson’s disease. In 
contrast, a signiﬁcant impact of cognitive impairment on
QoL of patients with Parkinson’s Disease was not
revealed. Treatment of depressive symptoms and preven-
tion of motor complications in PD patients may improve
considerably their Quality of Life.
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OBJECTIVES: Parkinson’s Disease (PD) is a chronic neu-
rological disease with disabling motor symptoms such as
tremor and rigidity, which may occur intermittently. The
DIREQT trial is an open label randomised trial designed
to study the effects of Duodopa (intra-intestinal admini-
stration of l-DOPA) compared to conventional oral
therapy of PD. DIREQT has three phases: 1) two weeks
pre-study phase; and 2) two weeks of Duodopa followed
by two weeks of conventional therapy—or vice versa; 
C: 6 months follow-up with conventional therapy or
Duodopa depending on patient preferences. Since PD
symptoms ﬂuctuate from hour to hour, standard methods
for evaluating quality of life are less suitable. The aim of
this paper is to describe a novel method for assessing
outcome in PD. METHODS: The Clinitrac system 
consists of a handheld computer (PDA) with a mobile
telephone. The PDA is pre-programmed with PD ques-
tionnaires (UPDRS, PSAA, PDQ-39) and generic quality
of life (QoL) instruments (TTO, 15D). Patients receive
notiﬁcation to ﬁll in the forms through the PDA at 8 AM,
noon, 4 PM and 8PM. Entries are automatically trans-
mitted to a central database via the mobile phone. If the
patient does not respond within 15 minutes, the data will
be reported missing and later entry is not allowed. The
principal investigator and a research nurse have access 
to the database, supervise the data collection and may
contact patients with high missing rates. RESULTS:
During the period August 2002 through November 2002
in total 12 patients have been included in the study. All
were able to use the PDA in spite of severe PD symptoms.
The rate of compliance with scheduled data entries varied
between 77% and 97%. CONCLUSION: Clinitrac seems
to offer a system that is acceptable to the patient for
repeated QoL measurements during one single day. Com-
pliance with the scheduled data entries is excellent, but
validity of entries has not yet been established.
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OBJECTIVE: Parkinson’s disease (PD) has consistently
been shown to exert a negative inﬂuence on patient-
reported quality of life (QoL). Few studies have differen-
tiated between early and advanced disease. A study
focusing on patients with advanced disease was desired
because it is expected that all patients will ultimately
experience an advanced form of PD, and that this infor-
mation would be useful for patients, caregivers, and
health care administrators. The objective of this study
was to assess the impact of sumanirole, a new, highly
selective D2 dopamine receptor agonist, on the QoL of
patients with advanced PD. METHODS: A double-blind,
